-
公开(公告)号：US07855278B2
公开(公告)日：2010-12-21
申请号：US11932861
申请日：2007-10-31
Applicant: Diane Pennica , Victoria Smith , William I. Wood
Inventor： Diane Pennica , Victoria Smith , William I. Wood
CPC classification number: C12N15/1034 , A61K38/1709 , A61K2039/505 , C07K14/47 , C07K2319/00 , C12N15/85 , G01N33/574 , A61K2300/00
Abstract: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Abstract translation: 本发明涉及与Stra6，鼠视黄酸反应性蛋白质以及编码这些多肽的核酸分子具有序列相似性的新型多肽。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。
-
公开(公告)号：US20080311621A1
公开(公告)日：2008-12-18
申请号：US12132350
申请日：2008-06-03
Applicant: Arnold J. Levine , Diane Pennica
Inventor： Arnold J. Levine , Diane Pennica
CPC classification number: G01N33/57484 , C07K14/47 , C07K2317/24 , C07K2319/02 , G01N33/68
Abstract: DNAs are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.
Abstract translation: 提供DNA，其基因至少被Wnt-1诱导。 还提供了编码那些多肽的核酸分子，以及包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的多肽的嵌合多肽分子，与多肽结合的抗体，以及用于产生多肽的方法。
-
公开(公告)号：US06472585B1
公开(公告)日：2002-10-29
申请号：US09648183
申请日：2000-08-25
Applicant: David Botstein , Audrey Goddard , David A. Lawrence , Diane Pennica , Margaret Ann Roy , William I. Wood
Inventor： David Botstein , Audrey Goddard , David A. Lawrence , Diane Pennica , Margaret Ann Roy , William I. Wood
IPC: A01K67027
CPC classification number: C07K14/52 , A01K2217/05 , A61K38/00 , C07K14/47 , C07K14/4703 , C07K16/18 , C07K16/24 , C07K2317/24 , C07K2319/00 , C07K2319/02 , G01N2500/00
Abstract: The invention concerns composititions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the cardiotrophin-1 polypeptide encoded by the amplified gene is believed to be a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and may act as a predictor of the prognosis of tumor treatment.
Abstract translation: 本发明涉及用于诊断和治疗哺乳动物（包括人）中的肿瘤细胞生长和增殖的复合和方法。 本发明基于在肿瘤细胞基因组中扩增的心肌营养因子-1基因的鉴定。 预期这种基因扩增与基因产物的过表达有关，并有助于肿瘤发生。 因此，被扩增的基因编码的心肌营养因子-1多肽被认为是某些癌症的诊断和/或治疗（包括预防）的有用靶标，并且可以作为肿瘤治疗预后的预测因子。
-
公开(公告)号：US06261837B1
公开(公告)日：2001-07-17
申请号：US09105412
申请日：1998-06-26
Applicant: Arthur D. Levinson , Diane Pennica , William J. Kohr , Gordon A. Vehar , David V. Goeddel , Elizabeth M. Yelverton , Christian C. Simonsen
Inventor： Arthur D. Levinson , Diane Pennica , William J. Kohr , Gordon A. Vehar , David V. Goeddel , Elizabeth M. Yelverton , Christian C. Simonsen
IPC: C12N516
CPC classification number: C12N9/0028 , C12N9/6459 , C12N15/85 , C12N2800/108 , C12N2830/00 , C12N2830/55 , C12Y304/21069
Abstract: A method for producing tissue plasminogen activator (t-PA) in eukaryotic host cells is disclosed. Enhanced levels of t-PA production are obtained by co-amplification of the t-PA gene through treatment of cultures transformed with mutant or wild type DHFR with methotrexate.
Abstract translation: 公开了一种在真核宿主细胞中产生组织纤溶酶原激活物（t-PA）的方法。 通过用甲氨蝶呤处理用突变体或野生型DHFR转化的培养物共同扩增t-PA基因，获得增强的t-PA产生水平。
-
公开(公告)号：US5728566A
公开(公告)日：1998-03-17
申请号：US483571
申请日：1995-06-06
Applicant: David V. Goeddel , William J. Kohr , Diane Pennica , Gordon A. Vehar
Inventor： David V. Goeddel , William J. Kohr , Diane Pennica , Gordon A. Vehar
IPC: A61K38/00 , C12N1/21 , C12N9/06 , C12N9/72 , C12N15/58 , C12N15/71 , C12P20060101 , C12N9/64 , A61K38/49 , C12N15/55
CPC classification number: C12N15/71 , C12N9/003 , C12N9/6459 , C12Y304/21069 , A61K38/00
Abstract: Tissue plasminogen activator (t-PA) derivatives are produced in useful quantifies using recombinant DNA techniques. Specific derivatives include amino acid deletion derivatives and amino acid substitution derivatives. A deletion derivative lacking the N-terminal first 68 amino acids is specifically exemplified having requisite t-PA characteristics. The invention disclosed thus enables the production of t-PA derivatives via recombinant means. Methods, expression vehicles and various host cells useful in the production of said t-PA derivatives are also disclosed.
Abstract translation: 使用重组DNA技术有效量化组织纤溶酶原激活物（t-PA）衍生物。 具体的衍生物包括氨基酸缺失衍生物和氨基酸取代衍生物。 具有必需的t-PA特征的具体示例是缺少N-末端第68个氨基酸的缺失衍生物。 因此，所公开的本发明能够通过重组方式生产t-PA衍生物。 还公开了可用于生产所述t-PA衍生物的方法，表达载体和各种宿主细胞。
-
Patent Agency Ranking
公开(公告)号：US5728565A
公开(公告)日：1998-03-17
申请号：US210179
申请日：1994-03-17
Applicant: David V. Goeddel , William J. Kohr , Diane Pennica , Gordon A. Vehar
Inventor： David V. Goeddel , William J. Kohr , Diane Pennica , Gordon A. Vehar
IPC: A61K38/00 , C12N1/21 , C12N9/06 , C12N9/72 , C12N15/58 , C12N15/71 , C12P20060101 , C12N5/10 , C12N9/64 , C12N15/55
CPC classification number: C12N15/71 , C12N9/003 , C12N9/6459 , C12Y304/21069 , A61K38/00
Abstract: Tissue plasminogen activator (t-PA) derivatives are produced in useful quantities using recombinant DNA techniques. Specific derivatives include amino acid deletion derivatives and amino acid substitution derivatives. A deletion derivative lacking the N-terminal first 68 amino acids is specifically exemplified having requisite t-PA characteristics. The invention disclosed thus enables the production of t-PA derivatives via recombinant means. Methods, expression vehicles and various host cells useful in the production of said t-PA derivatives are also disclosed.
Abstract translation: 组织纤溶酶原激活物（t-PA）衍生物使用重组DNA技术以有用的量产生。 具体的衍生物包括氨基酸缺失衍生物和氨基酸取代衍生物。 具有必需的t-PA特征的具体示例是缺少N-末端第68个氨基酸的缺失衍生物。 因此，所公开的本发明能够通过重组方式生产t-PA衍生物。 还公开了可用于生产所述t-PA衍生物的方法，表达载体和各种宿主细胞。
-
公开(公告)号：US5679545A
公开(公告)日：1997-10-21
申请号：US443952
申请日：1995-05-17
Applicant: Joffre Baker , Kenneth Chien , Kathleen King , Diane Pennica , William Wood
Inventor： Joffre Baker , Kenneth Chien , Kathleen King , Diane Pennica , William Wood
IPC: G01N33/53 , A61K38/00 , C07K14/52 , C07K16/24 , C12N5/10 , C12N15/02 , C12N15/09 , C12N15/19 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , C12R1/91 , G01N33/68 , C12N15/00 , C07H21/04 , C12N15/63 , C12N15/85
CPC classification number: C12Q1/025 , C07K14/52 , G01N33/6872 , A01K2217/05 , A61K38/00 , G01N2500/00 , Y10S930/14
Abstract: Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. These CT-1 molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
Abstract translation: 公开了分离的CT-1，编码CT-1的分离的DNA，以及制备CT-1的重组或合成方法。 这些CT-1分子显示出影响增生活性和神经活性。 因此，这些化合物或其拮抗剂可用于治疗心力衰竭，心律不齐症，肌力障碍和神经障碍。
-
8.发明授权
公开(公告)号：US5571675A
公开(公告)日：1996-11-05
申请号：US444083
申请日：1995-05-17
Applicant: Joffre Baker , Kenneth Chien , Kathleen King , Diane Pennica , William Wood
Inventor： Joffre Baker , Kenneth Chien , Kathleen King , Diane Pennica , William Wood
IPC: G01N33/53 , A61K38/00 , C07K14/52 , C07K16/24 , C12N5/10 , C12N15/02 , C12N15/09 , C12N15/19 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , C12R1/91 , G01N33/68 , C07H21/04 , C12P19/34
CPC classification number: C12Q1/025 , C07K14/52 , G01N33/6872 , A01K2217/05 , A61K38/00 , G01N2500/00 , Y10S930/14
Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
Abstract translation: 公开了分离的CHF，编码CHF的分离的DNA，以及制备CHF的重组或合成方法。 显示这些CHF分子影响增生活性和神经活性。 因此，这些化合物或其拮抗剂可用于治疗心力衰竭，心律不齐症，肌力障碍和神经障碍。
-
公开(公告)号：US5424198A
公开(公告)日：1995-06-13
申请号：US162354
申请日：1993-12-03
Applicant: Arthur D. Levinson , Diane Pennica , William J. Kohr , Gordon A. Vehar , David V. Goeddel , Elizabeth M. Yelverton , Christian C. Simonsen
Inventor： Arthur D. Levinson , Diane Pennica , William J. Kohr , Gordon A. Vehar , David V. Goeddel , Elizabeth M. Yelverton , Christian C. Simonsen
CPC classification number: C12N9/0028 , C12N15/85 , C12N9/6459 , C12Y304/21069 , C12N2800/108 , C12N2830/00 , C12N2830/55
Abstract: A method for producing tissue plasminogen activator (t-PA)in eukaroytic host cells is disclosed. Enhanced levels of t-PA production are obtained by co-amplification of the t-PA gene through treatment of cultures transformed with mutant or wild-type DHFR with methotrexate.
Abstract translation: 公开了一种用于在真核细胞宿主细胞中产生组织纤溶酶原激活物（t-PA）的方法。 通过用甲氨蝶呤处理用突变体或野生型DHFR转化的培养物共同扩增t-PA基因，获得增强的t-PA产生水平。
-
公开(公告)号：US08138152B2
公开(公告)日：2012-03-20
申请号：US12537888
申请日：2009-08-07
Applicant: Luc Desnoyers , Ellen H. Filvaroff , Diane Pennica
Inventor： Luc Desnoyers , Ellen H. Filvaroff , Diane Pennica
CPC classification number: C07K14/475 , A61K38/00 , C07K14/47
Abstract: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or degenerative cartilagenous disorders, including arthritis, comprising the administration of WISP polypeptide. Optionally, the administration may be in combination with one or more cartilage agents (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor). Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of WISP polypeptide in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of chondrocytes previously treated with an effective amount of WISP polypeptide.
Abstract translation: 本发明涉及软骨的治疗和修复方法，包括损伤的软骨或包括关节炎在内的退行性软骨疾病，包括施用WISP多肽。 任选地，给药可以与一种或多种软骨剂（例如肽生长因子，分解代谢拮抗剂，骨，滑膜，抗炎因子）组合。 或者，该方法提供了由损伤或退行性软骨障碍损伤的软骨的治疗和修复，包括与标准手术技术组合施用WISP多肽。 或者，该方法提供对由损伤或退行性软骨障碍损伤的软骨的治疗和修复，包括施用有效量的WISP多肽以前治疗的软骨细胞。
-
-
-
-
-
-
-
-
-
Search Results
60
records
(took 0.029 seconds)
